Major Depressive Disorder Clinical Trial
— CX157-200Official title:
A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder
Verified date | June 2012 |
Source | CeNeRx BioPharma Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of CX157 in these subjects.
Status | Completed |
Enrollment | 285 |
Est. completion date | July 2009 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Male or female = 18 years of age and <60 years - Able to read, understand, converse in English - Willing to comply with diet restrictions, concomitant medication restrictions, & all study requirements - Good general health as ascertained by:Medical history, Physical exam, Supine & standing vital signs, Clinical lab evaluations, 12-lead Electrocardiogram (ECG) - Diagnosis of MDD; - A total score =>40 on the IDS-SR30 assessed via IVRS at Screening and Randomization Exclusion Criteria: - Subject's current MDD episode is >2 years - History of Substance Use Disorder at Screening or 12 months prior (except for nicotine) - Current diagnosis of Obsessive-Compulsive Disorder; - Panic Disorder or Post-Traumatic Stress Disorder; - Anorexia nervosa, Bulimia nervosa, or eating disorder not otherwise specified; - Any Axis I Disorder clinically predominant to their MDD (within 6 mo); - Presence of psychotic features with current depressive episode; - Antisocial or Borderline Personality Disorder - At risk for suicide - Lack of response to >2 trials of adequate dose & duration of antidepressants of different mechanistic classes - Electroconvulsive therapy within 1 year of Screening - Subject has taken any psychoactive drug within 2 weeks of Randomization - History of cardiac abnormalities including abnormal vital sign measurements - Clinically significant abnormal ECG at Screening - History within past 2 years of: Significant head trauma; - Surgical procedure involving brain or meninges; Encephalitis or meningitis; - Degenerative CNS disorder (Alzheimer's or Parkinson's); - Epilepsy; - Mental retardation - Clinically significant Liver Function Test (LFT) and other lab abnormalities - A history of hypothyroidism and treatment with a stable dosage of thyroid replacement medication for <6 months prior to Screening - A history of hyperthyroidism treated (medically or surgically) <6 months prior to Screening - Participation in a clinical investigation of a psychotropic drug within 90 days prior to Screening OR used any other investigational drug within 60 days prior to Screening - Presence of any medical history which includes: - Hypersensitivity to CX157 or excipients, other MAO inhibitors, or other phenylethylamines; - Diabetes mellitus Type I, uncontrolled Type II, or controlled Type II managed with insulin; Malignancy/chemotherapy within 2 years prior to Screening; - Malignancy >2 yrs may not preclude participation if the malignancy was local and without metastasis or recurrence and, if treated with chemotherapy, had no nervous system complications (e.g basal cell carcinoma); - Pheochromocytoma - Positive urine test for drugs of abuse (blood for alcohol) - Female subject who is pregnant or lactating - Poor likelihood of subject's cooperation or compliance |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | FutureSearch Trials | Austin | Texas |
United States | McLean Hospital | Belmont | Massachusetts |
United States | Southwestern Research, Inc. | Beverly Hills | California |
United States | Birmingham Research Group | Birmingham | Alabama |
United States | Northbrooke Research Center | Brown Deer | Wisconsin |
United States | CRI Worldwide, LLC | Clementon | New Jersey |
United States | Fieve Clinical Services | New York | New York |
United States | Midwest Center for Neurobehavioral Medicine | Oakbrook Terrace | Illinois |
United States | University of Pennsylvania School of Medicine | Philadelphia | Pennsylvania |
United States | Richard H. Weisler, M.D., P.A. | Raleigh | North Carolina |
United States | Capital Clinical Research Associates | Rockville | Maryland |
United States | Summit Research Network (Seattle), LLC | Seattle | Washington |
United States | The George Washington University | Washington | District of Columbia |
United States | Irving S. Kolin, M.D. | Winter Park | Florida |
Lead Sponsor | Collaborator |
---|---|
CeNeRx BioPharma Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Randomization in Montgomery and Asberg Depression Rating Scale (MADRS) | The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item checklist designed to measure the overall severity of depressive symptoms in patients with MDD [Montgomery, 1979]. Items are rated on a scale of 0-6, with scores ranging from 0 to 60 with 0 being symptom free and 60 being the most severe depression. MADRS was assessed at randomization and Weeks 1, 2, 4 and 6 of the study. | Randomization and study end (Week 6). | No |
Secondary | Montgomery and Asberg Depression Rating Scale (MADRS) Response Rate | MADRS is a 10-item checklist designed to measure the overall severity of depressive symptoms in patients with MDD [Montgomery, 1979]. Items are rated on a scale of 0-6, with scores ranging from 0 to 60 with 0 being symptom free and 60 being the most severe depression. Percentage of participants who achieved a reduction in total MADRS score of at least 50% or more as compared to baseline. MADRS was assessed at randomization and Weeks 1, 2, 4, and 6 of the study. MADRS Responder rate at Week 6 or the last available post treatment result (LOCF) is reported here. | Week 6 or the last available post treatment result (LOCF) | No |
Secondary | Montgomery and Asberg Depression Rating Scale (MADRS) Remitter Rate | Percentage of participants with total MADRS score of 11 or less. MADRS was assessed at randomization and Weeks 1, 2, 4, and 6 of the study. MADRS Remitter rate at Week 6 or the last available post treatment result (LOCF)is reported here. | Week 6 or the last available post treatment result (LOCF) | No |
Secondary | The Hospital Anxiety and Depression Scale (HADS) | HADS is a subject-rated questionnaire designed to detect states of anxiety and depression. The HADS consists of 14 questions relating to anxiety or depression, each with a choice of four responses [Zigmond, 1983]. These responses are numerically scored 0-3, with 0 representing the least severe response and 3 representing the most severe response. The highest possible total score is 42. HADS was assessed at randomization and Weeks 1, 2, 4, and 6 of the study. Change from randomization in the HADS total score at Week 6 or the last available post treatment result (LOCF) is reported here. | Randomization and Week 6 or the last available post treatment result (LOCF) | No |
Secondary | Inventory of Depressive Symptomatology 30 Item -Self Report (IDS -SR 30 Items) | IDSR-SR 30 measures the severity of depressive symptoms by subjects. This scale has 30 items. The minimum score is 0 and the maximum possible IDS-30 score is 90 (the highest severity). IDS-SR30 was administered at screening, randomization and Weeks 1, 2, 4, and 6. Change from randomization in the IDS-SR30 total score at Week 6 or the last available post treatment result (LOCF) is reported here. | Randomization and Week 6 or the last available post treatment result (LOCF) | No |
Secondary | Clinical Global Impression - Improvement of Illness (CGI-I) | The Clinical Global Impression - Improvement of Illness (CGI-I) was rated on a 7-point scale by the investigator to measure subject's total improvement compared to his/her condition at randomization according to the following scale: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. CGI-I was measured at Weeks 1, 2, 4 and 6. Percentage of participants "very much improved" and "much improved" at Week 6 or the last available post treatment result (LOCF) is reported here. | Week 6 or the last available post treatment result (LOCF) | No |
Secondary | Clinical Global Impression - Severity of Illness (CGI-S) | CGI-S measures the study rater's assessment of the severity of depression illness. CGI-S is rated on a scale of 1-7 as follows: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill patients. CGI-S was measured at randomization and Weeks 1, 2, 4 and 6. Percentage of subjects reported as normal, not at all ill; borderline mentally ill; and mildly ill is reported here at Week 6 or the last available post treatment result (LOCF). | Week 6 or the last available post treatment result (LOCF) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |